text
"['\nX. 이해관계자와의 거래내용\n1. 주주 이외의 이해관계자와의 거래\n(1) 당분기 및 전분기 중 회사와 매출 등 거래 또는 채권, 채무 잔액이 있는 특수관계자 현황은 다음과 같습니다.\n관 계\n회\xa0 \xa0\xa0 사\xa0 \xa0\xa0 명\n종속기업\n\xa0㈜유한화학 ,㈜유한메디카 ,㈜엠지, ㈜유한건강생활, YUHAN USA CORPORATION, YUHAN UZBEKISTAN,\xa0㈜워랜텍,\xa0애드파마㈜, YUHAN Hong Kong Limited, YUHAN ANZ Pty Ltd.\n관계기업 및 공동기업\n\xa0유한킴벌리㈜, ㈜유한크로락스, ㈜한국얀센,\xa0㈜유칼릭스,\xa0㈜이뮨온시아,  ㈜씨.앤.씨,\xa0㈜코스온, ㈜엔솔바이오사이언스,\xa0칭다오세브란스병원(유),\xa0파라투스에스피사모투자(합), ㈜아임뉴런바이오사이언스\n기타특수관계자\n\xa0㈜리드팜\n(2) 당분기 및 전분기 중 특수관계자와의 거래 내역은 다음과 같습니다.\n- 당분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0 ㈜유한화학\xa0\n7,789\n12,289\n-\n-\n-\n-\n-\n-\n36,795,968\n116,098,890\n\xa0 ㈜유한메디카\xa0\n-\n295\n460\n\xa0460\n-\n-\n-\n-\n-\n-\n\xa0 ㈜엠지\n-\n-\n-\n-\n-\n-\n-\n125,935\n267,553\n6,837,485\n\xa0 ㈜유한건강생활\n-\n2,036\n1,173\n5,290\n-\n-\n-\n-\n13,370\n53,915\n\xa0\xa0YUHAN UZBEKISTAN\n188,377\n261,679\n-\n-\n-\n-\n-\n-\n-\n-\n\xa0\xa0애드파마㈜\n-\n14,250\n29,291\n83,787\n2,110\n6,330\n-\n-\n250,000\n4,863,009\n\xa0\xa0㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n323,450\n1,103,932\n소 계\n196,166\n290,549\n30,924\n89,537\n2,110\n6,330\n-\n125,935\n37,650,341\n128,957,231\n(관계기업 및 공동기업)\n\xa0 ㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n13,260\n39,410\n\xa0 ㈜유한크로락스\n9,009\n20,837\n-\n-\n461,821\n1,140,233\n-\n2,198,000\n16,648,484\n41,137,145\n\xa0 유한킴벌리㈜\n1,146\n57,367\n-\n-\n-\n-\n-\n26,400,000\n109,397\n1,552,668\n\xa0 ㈜한국얀센\n-\n-\n157,663\n323,716\n-\n-\n-\n1,151,188\n8,620,310\n27,473,523\n\xa0 ㈜이뮨온시아\n-\n-\n936\n16,536\n20,760\n128,234\n-\n-\n-\n-\n\xa0 ㈜씨.앤.씨\n-\n9,068\n-\n-\n-\n-\n-\n-\n2,002,569\n5,893,507\n\xa0\xa0㈜코스온\n18,545\n37,091\n-\n-\n-\n-\n-\n-\n-\n340,299\n\xa0 ㈜엔솔바이오사이언스\n-\n-\n-\n-\n-\n-\n-\n-\n-\n155,746\n소 계\n28,700\n124,363\n158,599\n340,252\n482,581\n1,268,467\n-\n29,789,988\n27,394,020\n76,592,298\n(기타특수관계자)\n\xa0 ㈜리드팜\n680,353\n1,843,843\n-\n-\n-\n-\n-\n-\n1,860\n2,941\n합 계\n905,219\n2,258,755\n189,523\n429,789\n484,691\n1,274,797\n-\n29,915,923\n65,046,221\n205,552,470\n- 전분기\n\xa0(단위:천원)\n특수관계자의 명칭\n제상품매출\n임대, 용역수익\n기타(잡이익등)\n배당금수익\n매입등\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n3개월\n누적\n(종속기업)\n\xa0 ㈜유한화학\xa0\n-\n2,064\n-\n-\n396,986\n1,190,959\n-\n-\n41,846,179\n121,307,524\n\xa0 ㈜유한메디카\xa0\n-\n345\n-\n-\n-\n-\n-\n-\n-\n-\n\xa0 ㈜엠지\n-\n-\n-\n-\n-\n-\n-\n125,935\n3,937,211\n11,338,513\n\xa0 ㈜유한건강생활\n-\n-\n6,486\n19,458\n-\n-\n-\n-\n-\n-\n\xa0 YUHAN UZBEKISTAN\n275,222\n275,222\n-\n-\n-\n-\n-\n-\n-\n-\n\xa0 애드파마㈜\n28,500\n37,200\n25,272\n75,816\n800\n2,250\n-\n-\n-\n-\n\xa0 ㈜워랜텍\n-\n-\n-\n-\n-\n-\n-\n-\n337,130\n640,694\n소 계\n\xa0 303,722\n\xa0 314,831\n\xa0 \xa0 31,758\n\xa0 \xa0 95,274\n\xa0 397,786\n\xa0\xa0 1,193,209\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 -\xa0\n\xa0 125,935\n\xa046,120,520\n133,286,731\n(관계기업 및 공동기업)\n\xa0 ㈜유칼릭스\n-\n-\n-\n-\n-\n-\n-\n40,800\n13,181\n38,745\n\xa0 ㈜유한크로락스\n-\n-\n-\n-\n443,515\n1,153,514\n-\n5,495,000\n14,563,849\n38,139,403\n\xa0 유한킴벌리㈜\n-\n-\n-\n-\n-\n-\n-\n21,900,000\n-\n908,239\n\xa0 ㈜한국얀센\n-\n-\n81,512\n165,656\n-\n-\n-\n1,861,929\n9,212,464\n27,421,165\n\xa0 ㈜바이오니아\n-\n-\n-\n-\n-\n-\n-\n-\n-\n24\n\xa0 ㈜이뮨온시아\n-\n-\n11,537\n32,163\n-\n-\n-\n-\n-\n-\n\xa0 ㈜씨.앤.씨\n-\n6,312\n-\n-\n-\n-\n-\n-\n1,351,073\n4,299,864\n\xa0 ㈜엔솔바이오사이언스\n-\n-\n-\n-\n-\n-\n-\n-\n28,380\n28,380\n소 계\n-\n6,312\n93,049\n197,819\n443,515\n1,153,514\n-\n29,297,729\n25,168,947\n70,835,820\n(기타특수관계자)\n\xa0 ㈜리드팜\n489,144\n1,669,106\n-\n-\n-\n-\n-\n-\n-\n4,711\n합 계\n792,866\n1,990,249\n124,807\n293,093\n841,301\n2,346,723\n-\n29,423,664\n71,289,467\n204,127,262\n(3) 당분기말과 전기말 현재 특수관계자와의 채권ㆍ채무는 다음과 같습니다.\n\xa0(단위:천원)\n특수관계자 명칭\n매출채권\n매입채무\n미수금 등 기타자산\n예수보증금\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n당분기말\n전기말\n(종속기업)\n\xa0㈜유한화학\xa0\n-\n-\n9,009,967\n6,899,288\n-\n7,682,589\n-\n-\n\xa0㈜유한메디카\n506\n-\n-\n-\n-\n-\n400,000\n-\n\xa0㈜엠지\n-\n-\n-\n1,589,727\n1,015,935\n-\n-\n-\n\xa0㈜유한건강생활\n-\n-\n12,925\n-\n40,000,000\n-\n68,000\n376,000\n\xa0YUHAN UZBEKISTAN\n1,234,711\n898,452\n-\n-\n-\n-\n-\n-\n\xa0㈜워랜텍\n-\n-\n170,467\n274,537\n-\n-\n-\n-\n\xa0애드파마㈜\n-\n-\n-\n-\n6,380,672\n-\n-\n-\n소 계\n1,235,217\n898,452\n9,193,359\n8,763,552\n47,396,607\n7,682,589\n468,000\n376,000\n(관계기업 및 공동기업)\n\xa0㈜유칼릭스\n-\n-\n3,152\n5,781\n-\n-\n-\n-\n\xa0㈜유한크로락스\n508,003\n-\n12,388,725\n5,421,569\n-\n505,281\n-\n-\n\xa0유한킴벌리㈜\n-\n-\n120,337\n162,132\n-\n-\n-\n-\n\xa0㈜한국얀센\n85,109\n-\n3,296,826\n2,275,523\n-\n-\n-\n-\n\xa0㈜이뮨온시아\n-\n4,230\n-\n-\n-\n-\n-\n-\n\xa0㈜씨.앤.씨\n-\n-\n1,304,121\n530,886\n-\n-\n-\n-\n소 계\n593,112\n4,230\n17,113,161\n8,395,891\n-\n505,281\n-\n-\n(기타특수관계자)\n\xa0㈜리드팜\n551,483\n460,556\n-\n-\n-\n-\n-\n-\n합 계\n2,379,812\n1,363,238\n26,306,520\n17,159,443\n47,396,607\n8,187,870\n468,000\n376,000\n(4) 당분기 및 전분기 중 특수관계자와의 자금거래 내역은 다음과 같습니다.\n(단위: 천원)\n특수관계 구분\n회사명\n당분기\n전분기\n대여\n회수\n출자\n대여\n회수\n출자\n종속기업\n㈜유한화학(*)\n-\n-\n-\n-\n35,000,000\n35,000,000\nYUHAN USA CORPORATION\n-\n-\n3,545,700\n-\n-\n1,944,362\nYUHAN UZBEKISTAN\n-\n-\n-\n-\n-\n1,067,500\n애드파마㈜\n-\n-\n-\n-\n-\n2,000,000\n㈜워랜텍\n-\n-\n-\n-\n-\n2,000,000\nYUHAN Hong Kong Limited\n-\n-\n6,019,741\n-\n-\n-\nYUHAN ANZ Pty Ltd.\n-\n-\n1,965,045\n-\n-\n-\n관계기업 및 공동기업\n파라투스에스피사모투자(합)\n-\n-\n15,000,000\n-\n-\n-\n칭다오세브란스병원(유)\n-\n-\n-\n-\n-\n20,103,529\n㈜아임뉴런바이오사이언스\n-\n-\n6,000,900\n-\n-\n-\n(*)\xa0전분기\xa0㈜유한화학\xa0회수분은\xa0출자전환되었습니다.\xa0(5)\xa0당분기말 현재 회사가 특수관계자에게 제공하고 있는 지급보증 및 담보 내역은\xa0없습니다.\n(6) 회사는 등기이사 및 회사 기업활동의 계획, 운영 및 통제에 대한 중요한 권한과 책임을 가진 등기 임원을 주요 경영진으로 판단하고 있으며, 당분기 및 전분기 중 주요 경영진에 대한 보상금액은 다음과 같습니다.\n(단위:천원)\n구\xa0 분\n당분기\n전분기\n3개월\n누적\n3개월\n누적\n단기종업원급여\n758,653\n2,441,084\n784,942\n\xa02,284,574\n퇴직급여\n127,730\n383,188\n135,310\n\xa0405,931\n합\xa0 계\n886,383\n2,824,272\n920,252\n2,690,505\n']"
